Search results
Results from the WOW.Com Content Network
Astressin-B is a nonselective corticotropin releasing hormone antagonist that reduces the synthesis of adrenocorticotropic hormone and cortisol. [1] It reduces the synthesis of adrenocorticotropic hormone and improves the sexual drive of rats under stressing conditions. [2] Astressin-B is able to delay the emptying of solid food in mice. [3]
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6. [4] It was designated as a breakthrough therapy for breast cancer by the US Food and Drug Administration (FDA) in ...
Ovarian stimulation with the aromatase inhibitor letrozole has been proposed for ovulation induction in order to treat unexplained female infertility. In a multi-center study funded by the National Institute of Child Health and Development, ovarian stimulation with letrozole resulted in a significantly lower frequency of multiple gestation (i.e., twins or triplets) but also a lower frequency ...
For premium support please call: 800-290-4726 more ways to reach us
Elacestrant was not McDonnell’s first attempt at bringing a breast cancer drug to market. In 1996, his lab developed a similar drug, etacstil, which was the first oral medication in this class ...
A Corticotropin-releasing hormone antagonist (CRH antagonist) is a specific type of receptor antagonist that blocks the receptor sites for corticotropin-releasing hormone, also known as corticotropin-releasing factor (CRF), which synchronizes the behavioral, endocrine, autonomic, and immune responses to stress by controlling the hypothalamic-pituitary-adrenal axis (HPA axis). [1]
Danielle Fishel is sharing an update about her health, saying she has completed “active cancer treatment” following her announcement in August that she was diagnosed with DCIS, which stands ...
The International Classification of Diseases for Oncology (ICD-O) is a domain-specific extension of the International Statistical Classification of Diseases and Related Health Problems for tumor diseases. This classification is widely used by cancer registries. It is currently in its third revision (ICD-O-3). ICD-10 includes a list of ...